| Literature DB >> 9271323 |
N Thiounn1, F Pages, T Flam, E Tartour, V Mosseri, M Zerbib, P Beuzeboc, L Deneux, W H Fridman, B Debré.
Abstract
It has been reported that a high plasmatic concentration of interleukin-6 (IL-6) is correlated to a lack of response to immunotherapy in several malignancies, suggesting that IL-6 was either a marker of tumour aggressiveness or had only a predictive value of response to immunotherapy. To discriminate between these two possibilities, a retrospective study was performed in a series of 19 patients with metastatic renal cell carcinoma who did not respond to IL-2/IFNalpha/5-FU treatment. Serum levels of IL-6, C-reactive Protein (CRP), soluble IL-2-receptor (sIL-2R), M-CSF and neopterin were assayed before treatment. IL-6 showed a significant correlation with patients median survival time (P < 0.016), suggesting that serum concentration of IL-6 before treatment is a marker of tumour aggressiveness rather than a predictive parameter for an immunological response.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9271323 DOI： 10.1016/s0165-2478(97)00036-9
Source DB: PubMed Journal: Immunol Lett ISSN： 0165-2478 Impact factor: 3.685